Entero Therapeutics, Inc. (NASDAQ:GRDX) Sees Large Growth in Short Interest

Entero Therapeutics, Inc. (NASDAQ:GRDX) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 118,986 shares, a growth of 470.4% from the July 30th total of 20,859 shares. Based on an average daily trading volume, of 145,108 shares, the short-interest ratio is presently 0.8 days. Currently, 1.7% of the company’s shares are short sold.

Institutional Trading of Entero Therapeutics

A hedge fund recently bought a new position in Entero Therapeutics stock. DRW Securities LLC acquired a new position in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned about 1.45% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is owned by hedge funds and other institutional investors.

Entero Therapeutics Stock Down 0.7%

GRDX traded down $0.03 during trading on Friday, reaching $3.98. The company had a trading volume of 18,743 shares, compared to its average volume of 119,251. The business has a 50 day simple moving average of $3.78 and a 200-day simple moving average of $3.42. The stock has a market cap of $28.38 million, a P/E ratio of -2.09 and a beta of 1.86. Entero Therapeutics has a 52 week low of $1.87 and a 52 week high of $6.93.

Entero Therapeutics (NASDAQ:GRDX) last posted its quarterly earnings data on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.